This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Role of Ribose in Patients Diagnosed With Fibromyalgia

This study has suspended participant recruitment.
(Protocol Under Review)
Information provided by:
Bioenergy Life Science, Inc. Identifier:
First received: November 29, 2007
Last updated: March 10, 2008
Last verified: March 2008
The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

Condition Intervention
Fibromyalgia Dietary Supplement: D-ribose Other: dextrose

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: The Role of D-RIbose in Patients Diagnosed With Fibromyalgia

Resource links provided by NLM:

Further study details as provided by Bioenergy Life Science, Inc.:

Primary Outcome Measures:
  • Significant reduction in symptoms of pain and fatigue [ Time Frame: 3 weeks ]

Secondary Outcome Measures:
  • Demonstrate an improvement in ones quality of life [ Time Frame: 3 weeks ]

Estimated Enrollment: 200
Study Start Date: July 2006
Estimated Study Completion Date: July 2008
Estimated Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
D-ribose 5 grams TID orally
Dietary Supplement: D-ribose
5 grams administered orally TID
Other Name: Corvalen
Placebo Comparator: 2
Dextrose 5 grams TID
Other: dextrose
5 grams orally TID

Detailed Description:
Two hundred to three hundred subjects (equally distribued between placebo and D-ribose) between 18-78 years of age will comprise this study. The final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to TID dosing with approximately equal balance between the active and placebo arms.

Ages Eligible for Study:   18 Years to 78 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • previous diagnosis of fibromomyalgia by a MD
  • Has been diagnosed with fibromyalgia and are over 18 years of age
  • Does live in the United States

Exclusion Criteria:

  • does NOT have severe medication/chemical/supplement sensitivities
  • does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure)
  • does NOT have rheumatoid arthritis or gout
  • previous use of ribose
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00566514

United States, Minnesota
Bioenergy Life Science, Inc.
Minneapolis, Minnesota, United States, 55304
Sponsors and Collaborators
Bioenergy Life Science, Inc.
Principal Investigator: Jacob Teitelbaum, MD The Annapolis Center for Effective CFS/Fibromyalgia Therapies
Principal Investigator: Kent Holtorf, MD Hormone and Longevity Medical Center
  More Information

Responsible Party: Jacob Teitelbaum, MD, The Annapolis Center for Effective CFS/Fibromyalgia Therapies Identifier: NCT00566514     History of Changes
Other Study ID Numbers: 200604-7
Study First Received: November 29, 2007
Last Updated: March 10, 2008

Keywords provided by Bioenergy Life Science, Inc.:

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases processed this record on September 21, 2017